Yen A, Forbes M E, Varvayanis S, Tykocinski M L, Groger R K, Platko J D
Department of Pathology, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853.
J Cell Physiol. 1993 Nov;157(2):379-91. doi: 10.1002/jcp.1041570222.
The dependence of induced myelomonocytic cell differentiation, and regulation of the RB tumor suppressor gene during this process, on the c-fms gene product, the CSF-1 lymphokine receptor, was determined in HL-60 promyelocytic leukemia cells. Adding a monoclonal antibody with specificity for the c-fms gene product to cells treated with various inducers of myelomonocytic or macrophage differentiation, including retinoic acid and 1,25-dihydroxy vitamin D3, inhibited the rate of differentiation. During the period of inducer treatment usually preceding onset of differentiation, longer periods of antibody exposure caused greater inhibition of differentiation. In a stable HL-60 transfectant overexpressing the CSF-1 receptor at the cell surface due to a constitutively driven c-fms trans gene, the rate of differentiation was enhanced compared to the wild type cell, consistent with a positive regulatory role for the CSF-1 receptor. The anti-fms antibody caused much less inhibition of differentiation in the transfectants than in wild type cells, consistent with a larger number of receptors causing reduced sensitivity. During the induced metabolic cascade leading to differentiation, the typical early down regulation of RB gene expression was inhibited by the antibody. The antibody itself caused an increase in RB expression per cell, which offset the decrease normally caused by differentiation inducers (1,25-dihydroxy vitamin D3 and retinoic acid). The changes in RB expression preceded changes in the RB protein to the hypophosphorylated state. Most of the RB protein in proliferating cells was phosphorylated and no significant accumulation of hypophosphorylated RB protein occurred until after onset of G0 arrest. Thus the metabolic cascade leading to myelomonocytic differentiation of HL-60 cells appears to be driven by a function of the c-fms protein. Inhibiting that process by attacking this receptor impedes differentiation and also compromises the early down regulation of RB tumor suppressor gene expression which normally precedes differentiation. These findings provide additional support for a potential role for down regulating RB expression in promoting cell differentiation, and suggest the possibility that RB may be either a target or intermediate mediator of CSF-1 actions.
在HL-60早幼粒细胞白血病细胞中,确定了诱导髓单核细胞分化以及在此过程中RB肿瘤抑制基因的调控对c-fms基因产物(CSF-1淋巴因子受体)的依赖性。将对c-fms基因产物具有特异性的单克隆抗体添加到用各种髓单核细胞或巨噬细胞分化诱导剂(包括视黄酸和1,25-二羟基维生素D3)处理的细胞中,可抑制分化速率。在通常先于分化开始的诱导剂处理期间,抗体暴露时间越长,对分化的抑制作用越大。在由于组成型驱动的c-fms转基因而在细胞表面过表达CSF-1受体的稳定HL-60转染子中,与野生型细胞相比,分化速率提高,这与CSF-1受体的正向调节作用一致。抗fms抗体对转染子分化的抑制作用比对野生型细胞的抑制作用小得多,这与受体数量增加导致敏感性降低一致。在导致分化的诱导代谢级联反应中,抗体抑制了RB基因表达典型的早期下调。抗体本身导致每个细胞中RB表达增加,抵消了分化诱导剂(1,25-二羟基维生素D3和视黄酸)通常引起的减少。RB表达的变化先于RB蛋白转变为低磷酸化状态。增殖细胞中的大多数RB蛋白是磷酸化的,直到G0期停滞开始后才出现低磷酸化RB蛋白的显著积累。因此,导致HL-60细胞髓单核细胞分化的代谢级联反应似乎是由c-fms蛋白的功能驱动的。通过攻击该受体来抑制该过程会阻碍分化,并且还会损害通常在分化之前的RB肿瘤抑制基因表达的早期下调。这些发现为下调RB表达在促进细胞分化中的潜在作用提供了额外支持,并表明RB可能是CSF-1作用的靶标或中间介质。